{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:50:51Z","timestamp":1767703851390,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["Novartis Pharma"],"award-info":[{"award-number":["Novartis Pharma"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Migraine is a primary headache disorder characterized by recurrent attacks that may have a significant impact on patients\u2019 daily life. Treatment options must often be re-evaluated in light of efficacy, tolerability and compliance issues. Few data on commonly applied treatment algorithms and treatment failures have existed in Germany in 2017\/2018. The PANORAMA survey was designed to explore and characterize the migraine healthcare landscape and to demonstrate the medical treatment need at that time in Germany.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Three different questionnaires were used to assess the profile of the 119 participating centers, characterize migraine patients at centers and evaluate qualitative aspects of the current migraine healthcare situation from a physician\u00b4s professional perspective. Data were analyzed as observed and summarized by descriptive statistics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The results demonstrate that once referred to a migraine specialist, the majority of patients continue to be treated at a specialist. At specialized centers, 41.6\u2009% of migraine patients receive prophylactic treatment. 45.4\u2009% of prophylactic treatments are initiated with a beta-blocker and 28.1\u2009% with an anti-epileptic. Pivotal factors to initiate prophylactic treatment are migraine attack frequency and intensity (58.0\u2009%). Treatment decisions are largely based on prior \/ concomitant diseases and physical constitution of the patient (52.1\u2009%). Following an inadequate treatment, most patients either switch substance class or discontinue prophylactic treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PANORAMA gives a comprehensive overview of the migraine healthcare landscape in Germany in 2017\/2018, elucidates a lack of common treatment algorithms and reveals a high demand for defined therapy strategies and new prophylactic treatment going forwards.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-021-01316-5","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T08:02:48Z","timestamp":1631174568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Migraine patients in Germany - need for medical recognition and new preventive treatments: results from the PANORAMA survey"],"prefix":"10.1186","volume":"22","author":[{"given":"M.","family":"Koch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Katsarava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Baufeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gendolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Straube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"von Pannwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. E.","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ortler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"issue":"1","key":"1316_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s10194-016-0699-5","volume":"17","author":"TJ Steiner","year":"2016","unstructured":"Steiner TJ, Stovner LJ, Vos T (2016) GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain 17(1):104. doi:https:\/\/doi.org\/10.1186\/s10194-016-0699-5","journal-title":"J Headache Pain"},{"issue":"1","key":"1316_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s10194-018-0907-6","volume":"19","author":"P Vo","year":"2018","unstructured":"Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S (2018) Patients\u2019 perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain 19(1):82. doi:https:\/\/doi.org\/10.1186\/s10194-018-0907-6","journal-title":"J Headache Pain"},{"key":"1316_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1129-2377-15-31","volume":"15","author":"TJ Steiner","year":"2014","unstructured":"Steiner TJ, Stovner LJ, Katsarava Z et al (2014) The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 15:31. doi:https:\/\/doi.org\/10.1186\/1129-2377-15-31","journal-title":"J Headache Pain"},{"issue":"4","key":"1316_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1046\/j.1526-4610.2003.03067.x","volume":"43","author":"TS Gibbs","year":"2003","unstructured":"Gibbs TS, Fleischer AB, Feldman SR, Sam MC, O\u2019Donovan CA (2003) Health care utilization in patients with migraine: demographics and patterns of care in the ambulatory setting. Headache 43(4):330\u2013335. doi:https:\/\/doi.org\/10.1046\/j.1526-4610.2003.03067.x","journal-title":"Headache"},{"issue":"2","key":"1316_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1526-4610.1998.3802087.x","volume":"38","author":"RB Lipton","year":"1998","unstructured":"Lipton RB, Stewart WF, Simon D (1998) Medical consultation for migraine: results from the American Migraine Study. Headache 38(2):87\u201396. doi:https:\/\/doi.org\/10.1046\/j.1526-4610.1998.3802087.x","journal-title":"Headache"},{"key":"1316_CR6","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.2147\/JPR.S128143","volume":"10","author":"M Giamberardino","year":"2017","unstructured":"Giamberardino M, Affaitati G, Costantini R, Cipollone F, Martelletti P (2017) Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. J Pain Res 10:2751\u20132760. doi:https:\/\/doi.org\/10.2147\/JPR.S128143","journal-title":"J Pain Res"},{"issue":"1","key":"1316_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm JMCP 20(1):22\u201333. doi:https:\/\/doi.org\/10.18553\/jmcp.2014.20.1.22","journal-title":"J Manag Care Pharm JMCP"},{"issue":"1","key":"1316_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1517\/14728214.2015.999040","volume":"20","author":"MA Giamberardino","year":"2015","unstructured":"Giamberardino MA, Martelletti P (2015) Emerging drugs for migraine treatment. Expert Opin Emerg Drugs 20(1):137\u2013147. doi:https:\/\/doi.org\/10.1517\/14728214.2015.999040","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"1316_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-018-0839-1","volume":"19","author":"Z Katsarava","year":"2018","unstructured":"Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ (2018) Poor medical care for people with migraine in Europe \u2013 evidence from the Eurolight study. J Headache Pain 19(1):10. doi:https:\/\/doi.org\/10.1186\/s10194-018-0839-1","journal-title":"J Headache Pain"},{"issue":"5","key":"1316_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10194-011-0356-y","volume":"12","author":"C Andr\u00e9e","year":"2011","unstructured":"Andr\u00e9e C, Stovner LJ, Steiner TJ et al (2011) The Eurolight project: the impact of primary headache disorders in Europe. Description of methods. J Headache Pain 12(5):541\u2013549. doi:https:\/\/doi.org\/10.1007\/s10194-011-0356-y","journal-title":"J Headache Pain"},{"key":"1316_CR11","doi-asserted-by":"publisher","first-page":"107528","DOI":"10.1016\/j.pharmthera.2020.107528","volume":"12","author":"T de Vries","year":"2020","unstructured":"de Vries T, Villal\u00f3n CM, MaassenVanDenBrink A (2020) Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. Published online March 12:107528. doi:https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107528","journal-title":"Published online March"},{"doi-asserted-by":"publisher","unstructured":"Liampas I, Siokas V, Brotis A, Vikelis M, Dardiotis E. Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta-Analysis. Headache Published online April 30, 2020. doi:https:\/\/doi.org\/10.1111\/head.13828","key":"1316_CR12","DOI":"10.1111\/head.13828"},{"doi-asserted-by":"publisher","unstructured":"Tseng P-T, Yang C-P, Su K-P et al (2020) The association between melatonin and episodic migraine: a pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. J Pineal Res Published online April 29:e12663. doi:https:\/\/doi.org\/10.1111\/jpi.12663","key":"1316_CR13","DOI":"10.1111\/jpi.12663"},{"doi-asserted-by":"publisher","unstructured":"Visser EJ, Drummond PD, Lee-Visser JLA. Reduction in Migraine and Headache Frequency and Intensity with Combined Antioxidant Prophylaxis (N-acetylcysteine, Vitamin E and Vitamin C: NEC): A Randomized Sham-Controlled Pilot Study. Pain Pract Off J World Inst Pain Published online April 19, 2020. doi:https:\/\/doi.org\/10.1111\/papr.12902","key":"1316_CR14","DOI":"10.1111\/papr.12902"},{"doi-asserted-by":"publisher","unstructured":"Locher C, Kossowsky J, Koechlin H et al. Efficacy, Safety, and Acceptability of Pharmacologic Treatments for Pediatric Migraine Prophylaxis: A Systematic Review and Network Meta-analysis. JAMA Pediatr Published online February 10, 2020. doi:https:\/\/doi.org\/10.1001\/jamapediatrics.2019.5856","key":"1316_CR15","DOI":"10.1001\/jamapediatrics.2019.5856"},{"doi-asserted-by":"publisher","unstructured":"Frederiksen SD, Bekker-Nielsen Dunbar M, Snoer AH, Deen M, Edvinsson L. Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Case-Control and Case-Crossover Settings: A Systematic Review and Meta-Analysis. Headache Published online April 15, 2020. doi:https:\/\/doi.org\/10.1111\/head.13802","key":"1316_CR16","DOI":"10.1111\/head.13802"},{"issue":"1","key":"1316_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12883-020-01633-3","volume":"20","author":"H Deng","year":"2020","unstructured":"Deng H, Li G-G, Nie H et al (2020) Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. BMC Neurol 20(1):57. doi:https:\/\/doi.org\/10.1186\/s12883-020-01633-3","journal-title":"BMC Neurol"},{"issue":"22","key":"1316_CR18","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y et al (2017) A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 377(22):2123\u20132132. doi:https:\/\/doi.org\/10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"issue":"1","key":"1316_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s10194-020-01099-1","volume":"21","author":"B M\u00fcller","year":"2020","unstructured":"M\u00fcller B, Dresler T, Gaul C et al (2020) Use of outpatient medical care by headache patients in Germany: a population-based cross-sectional study. J Headache Pain 21(1):49. doi:https:\/\/doi.org\/10.1186\/s10194-020-01099-1","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01316-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-021-01316-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01316-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T08:02:54Z","timestamp":1631174574000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-021-01316-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1316"],"URL":"https:\/\/doi.org\/10.1186\/s10194-021-01316-5","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"type":"print","value":"1129-2369"},{"type":"electronic","value":"1129-2377"}],"subject":[],"published":{"date-parts":[[2021,9,9]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Approval by an institutional review board for this data collection was not required according to local regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MK, CB, KS and SO are employees of Novartis Pharma GmbH. ZK received honoraria from Allergan GmbH, Merck KGaA, TEVA GmbH, Lilly GmbH, Novartis Pharma GmbH and Daiichi Sankyo GmbH. AG received honoraria from Allergan GmbH, Reckitt Benckiser GmbH, St. Jude Medical Inc., Bayer AG, Gr\u00fcnenthal GmbH, Mundipharma GmbH, Zahn\u00e4rztekammer KVNO (Kassen\u00e4rztliche Vereinigung Nordrhein), GAF, Novartis Pharma GmbH, Lilly GmbH, TEVA GmbH, Hormosan Pharma GmbH and Allergan\/Abbvie GmbH & Co. KG. AS received honoraria for consulting and lectures within the past three years from Allergan GmbH, Bayer AG, Lilly GmbH, Novartis Pharma GmbH, Sanofi-Aventis GmbH and TEVA GmbH. WvP received honoraria for consulting, lectures and study activities from Bayer Vital GmbH, Biogen GmbH, Merck Serono GmbH, Novartis Pharma GmbH, Roche Pharma AG, TEVA GmbH, Sanofi-Aventis GmbH, STADA Pharm GmbH and UCB Pharma GmbH. WEH received honoraria for consulting from Desitin Arzneimittel GmbH, Bayer AG, TEVA GmbH and Novartis Pharma GmbH, and for lectures from TEVA GmbH and Novartis Pharma GmbH.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}